ArticleEmerging microbes & infections2017
A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
Article in Emerging microbes & infections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.Cell reports · 2024Article
- Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.bioRxiv : the preprint server for biology · 2024Article
- Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.Vaccines · 2023Review
- Article
- Vaccination in patients with kidney failure: lessons from COVID-19.Nature reviews. Nephrology · 2022Review
- Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.Current opinion in virology · 2022Review
- The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections.Scientific reports · 2022Article
- Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein.Frontiers in microbiology · 2022Article
- Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.Journal of drug delivery science and technology · 2022Review
- An update on emerging therapeutics to combat COVID-19.Basic & clinical pharmacology & toxicology · 2021Review
- The impact of high-resolution structural data on stemming the COVID-19 pandemic.Current opinion in virology · 2021Review
- Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.Cell host & microbe · 2021Article
- Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.Reviews in medical virology · 2021Review
- SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development.Frontiers in molecular biosciences · 2021Review
- Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review.Journal of medical virology · 2021Review
- Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19.Nanomedicine (London, England) · 2020Review
- Coronaviruses pandemics: Can neutralizing antibodies help?Life sciences · 2020Review
- Review
- Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.Virus research · 2020Article
- Article
Corrections and comments
- Erratum for
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This corrects the article DOI: 10.1038/emi.2017.18.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.